SVA
Sinovac Biotech·NASDAQ
--
--(--)
--
--(--)
2.50 / 10
Underperform
Sentiment metrics score 5/10, revealing neutral capital movement with challenges in multiple fund flow categories. Analyst consensus is overwhelmingly bullish (Strong Buy 100%), but historical win rates are 0.0%, and the current price trend is falling. This disconnect between positive analyst ratings and poor historical performance warrants skepticism. The Nasdaq non-compliance notice adds additional risk.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-04-22
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of SVA?
- SVA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 2.50/10 (Underperform).
